Our findings suggest that GRASLND is a potential marker for prognostic and immunotherapeutic response determination in SKCM patients, and an in-depth study of its functional mechanism may provide new targets and therapeutic strategies for melanoma immunotherapy. This evidence concerns the gene GRASLND and melanoma.